AI with Swarm Intelligence Detects COVID-19 in Data Stored in Decentralized Fashion
By LabMedica International staff writers Posted on 27 May 2021 |

Illustration
Using a principle called “swarm learning” an international research team has trained artificial intelligence (AI) algorithms to detect blood cancer, lung diseases and COVID-19 in data stored in a decentralized fashion.
This approach by experts from the German Center for Neurodegenerative Diseases (DZNE; Bonn, Germany), the University of Bonn (Bonn, Germany) and Hewlett Packard Enterprise (HPE; Houston, TX, USA) has advantages over conventional methods since it inherently provides privacy preservation technologies, which facilitates cross-site analysis of scientific data. Swarm learning could thus significantly promote and accelerate collaboration and information exchange in research, especially in the field of medicine.
Science and medicine are becoming increasingly digital. Analyzing the resulting volumes of information - known as “big data” - is considered a key to better treatment options. However, the exchange of medical research data across different locations or even between countries is subject to data protection and data sovereignty regulations. In practice, these requirements can usually only be implemented with significant effort. In addition, there are technical barriers: For example, when huge amounts of data have to be transferred digitally, data lines can quickly reach their performance limits. In view of these conditions, many medical studies are locally confined and cannot utilize data that is available elsewhere.
In light of this, an international research collaboration tested a novel approach for evaluating research data stored in a decentralized fashion. The basis for this was the still young “Swarm Learning” technology developed by HPE. In addition to the IT company, numerous research institutions from Greece, the Netherlands and Germany - including members of the “German COVID-19 OMICS Initiative” (DeCOI) - participated in this study.
Swarm Learning combines a special kind of information exchange across different nodes of a network with methods from the toolbox of “machine learning”, a branch of AI. The linchpin of machine learning are algorithms that are trained on data to detect patterns in it - and that consequently acquire the ability to recognize the learned patterns in other data as well. With Swarm Learning, all research data remains on site. Only algorithms and parameters are shared - in a sense, lessons learned. Unlike “federated learning”, in which the data also remains locally, there is no centralized command center. Thus, the AI algorithms learn locally, namely on the basis of the data available at each network node. The learning outcomes of each node are collected as parameters through the blockchain and smartly processed by the system. The outcome, i. e. optimized parameters, are passed on to all parties. This process is repeated multiple times, gradually improving the algorithms’ ability to recognize patterns at each node of the network.
The researchers are now providing practical proof of this approach through the analysis of X-ray images of the lungs and of transcriptomes: The latter are data on the gene activity of cells. In the current study, the focus was specifically on immune cells circulating in the blood - in other words, white blood cells. The research team addressed a total of four infectious and non-infectious diseases: two variants of blood cancer (acute myeloid leukemia and acute lymphoblastic leukemia), as well as tuberculosis and COVID-19. The data included a total of more than 16,000 transcriptomes. The swarm learning network over which the data were distributed typically consisted of at least three and up to 32 nodes. Independently of the transcriptomes, the researchers analyzed about 100,000 chest X-ray images. These were from patients with fluid accumulation in the lung or other pathological findings as well as from individuals without anomalies. These data were distributed across three different nodes.
The analysis of both the transcriptomes and the X-ray images followed the same principle: First, the researchers fed their algorithms with subsets of the respective data set. This included information about which of the samples came from patients and which from individuals without findings. The learned pattern recognition for “sick” or “healthy” was then used to classify further data, in other words it was used to sort the data into samples with or without disease. The accuracy, i.e. the ability of the algorithms to distinguish between healthy and diseased individuals, was around 90% on average for the transcriptomes (each of the four diseases was evaluated separately); in the case of the X-ray data, it ranged from 76% to 86%. The study also found that Swarm Learning yielded significantly better results than when the nodes in the network learned separately.
“The methodology worked best in leukemia. In this disease, the signature of gene activity is particularly striking and thus easiest for artificial intelligence to detect. Infectious diseases are more variable. Nevertheless, the accuracy was also very high for tuberculosis and COVID-19. For X-ray data, the rate was somewhat lower, which is due to the lower data or image quality,” said Joachim Schultze, Director of Systems Medicine at the DZNE and professor at the Life & Medical Sciences Institute (LIMES) at the University of Bonn. “Our study thus proves that Swarm Learning can be successfully applied to very different data. In principle, this applies to any type of information for which pattern recognition by means of artificial intelligence is useful. Be it genome data, X-ray images, data from brain imaging or other complex data.”
Related Links:
German Center for Neurodegenerative Diseases (DZNE)
University of Bonn
Hewlett Packard Enterprise
This approach by experts from the German Center for Neurodegenerative Diseases (DZNE; Bonn, Germany), the University of Bonn (Bonn, Germany) and Hewlett Packard Enterprise (HPE; Houston, TX, USA) has advantages over conventional methods since it inherently provides privacy preservation technologies, which facilitates cross-site analysis of scientific data. Swarm learning could thus significantly promote and accelerate collaboration and information exchange in research, especially in the field of medicine.
Science and medicine are becoming increasingly digital. Analyzing the resulting volumes of information - known as “big data” - is considered a key to better treatment options. However, the exchange of medical research data across different locations or even between countries is subject to data protection and data sovereignty regulations. In practice, these requirements can usually only be implemented with significant effort. In addition, there are technical barriers: For example, when huge amounts of data have to be transferred digitally, data lines can quickly reach their performance limits. In view of these conditions, many medical studies are locally confined and cannot utilize data that is available elsewhere.
In light of this, an international research collaboration tested a novel approach for evaluating research data stored in a decentralized fashion. The basis for this was the still young “Swarm Learning” technology developed by HPE. In addition to the IT company, numerous research institutions from Greece, the Netherlands and Germany - including members of the “German COVID-19 OMICS Initiative” (DeCOI) - participated in this study.
Swarm Learning combines a special kind of information exchange across different nodes of a network with methods from the toolbox of “machine learning”, a branch of AI. The linchpin of machine learning are algorithms that are trained on data to detect patterns in it - and that consequently acquire the ability to recognize the learned patterns in other data as well. With Swarm Learning, all research data remains on site. Only algorithms and parameters are shared - in a sense, lessons learned. Unlike “federated learning”, in which the data also remains locally, there is no centralized command center. Thus, the AI algorithms learn locally, namely on the basis of the data available at each network node. The learning outcomes of each node are collected as parameters through the blockchain and smartly processed by the system. The outcome, i. e. optimized parameters, are passed on to all parties. This process is repeated multiple times, gradually improving the algorithms’ ability to recognize patterns at each node of the network.
The researchers are now providing practical proof of this approach through the analysis of X-ray images of the lungs and of transcriptomes: The latter are data on the gene activity of cells. In the current study, the focus was specifically on immune cells circulating in the blood - in other words, white blood cells. The research team addressed a total of four infectious and non-infectious diseases: two variants of blood cancer (acute myeloid leukemia and acute lymphoblastic leukemia), as well as tuberculosis and COVID-19. The data included a total of more than 16,000 transcriptomes. The swarm learning network over which the data were distributed typically consisted of at least three and up to 32 nodes. Independently of the transcriptomes, the researchers analyzed about 100,000 chest X-ray images. These were from patients with fluid accumulation in the lung or other pathological findings as well as from individuals without anomalies. These data were distributed across three different nodes.
The analysis of both the transcriptomes and the X-ray images followed the same principle: First, the researchers fed their algorithms with subsets of the respective data set. This included information about which of the samples came from patients and which from individuals without findings. The learned pattern recognition for “sick” or “healthy” was then used to classify further data, in other words it was used to sort the data into samples with or without disease. The accuracy, i.e. the ability of the algorithms to distinguish between healthy and diseased individuals, was around 90% on average for the transcriptomes (each of the four diseases was evaluated separately); in the case of the X-ray data, it ranged from 76% to 86%. The study also found that Swarm Learning yielded significantly better results than when the nodes in the network learned separately.
“The methodology worked best in leukemia. In this disease, the signature of gene activity is particularly striking and thus easiest for artificial intelligence to detect. Infectious diseases are more variable. Nevertheless, the accuracy was also very high for tuberculosis and COVID-19. For X-ray data, the rate was somewhat lower, which is due to the lower data or image quality,” said Joachim Schultze, Director of Systems Medicine at the DZNE and professor at the Life & Medical Sciences Institute (LIMES) at the University of Bonn. “Our study thus proves that Swarm Learning can be successfully applied to very different data. In principle, this applies to any type of information for which pattern recognition by means of artificial intelligence is useful. Be it genome data, X-ray images, data from brain imaging or other complex data.”
Related Links:
German Center for Neurodegenerative Diseases (DZNE)
University of Bonn
Hewlett Packard Enterprise
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more